ANNEXa-I

Stuart Connolly

Stuart Connolly is a Professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences. He became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University.

He has published more than 270 scientific articles in the field, and is currently a member of the editorial boards for a number of prominent cardiology journals, including Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology. His main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area.

He holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University.

Mike Sharma

Senior Scientist

Mike Sharma is Professor of Medicine (Neurology) at McMaster University and a vascular neurologist at Hamilton Health Sciences. He holds the Michael G DeGroote Chair in Stroke Prevention and leads the Brain Health and Stroke Program at PHRI. He is the Medical Director of the Regional Stroke Program at HHS.

After neurology training at Western, a stroke fellowship at the Montreal Neurologic Institute and the University of Ottawa, he completed an MSc in Clinical Epidemiology. He founded the Stroke Program at the University of Ottawa and joined PHRI in 2013. Mike is the Past Chair of the Canadian Stroke Consortium and was the Deputy Director of Clinical Affairs and Policy at the Canadian Stroke Network. He has held leadership positions in trials of novel antithrombotic approaches to stroke prevention and imaging/cognitive outcomes in large trials of stroke prevention. He led the imaging substudies in COMPASS and NAVIGATE ESUS that explored the impact of interventions on covert vascular disease as well as cognitive outcomes. Building on these findings he has been heavily involved with the development of FXIa inhibitors for stroke prevention. He led the multinational Phase II dose ranging AXIOMATIC SSP trial that established a dose of the small molecule FXIa inhibitor milvexian for stroke prevention. He currently leads the pivotal efficacy trial OCEANIC STROKE that seeks to establish the benefit of Asundexian and FXIa inhibition in secondary stroke prevention. In addition to other ongoing research, he and Raed Joundi lead PROSPECT – an international cohort study examining the determinants of cognitive and functional decline in those with a recent stroke.

Ashkan Shoamanesh

Senior Scientist

Ashkan Shoamanesh is an Associate Professor of Medicine (Division of Neurology) and a stroke neurologist at McMaster University, where he holds the Marta and Owen Boris Chair in Stroke Research and Care. He is the founding Director of the Hemorrhagic Stroke Research Program and a Senior Scientist at the Population Health Research Institute.

Shoamanesh’s clinical trials program focuses on advancing treatments and establishing new standards of care to prevent stroke or reduce stroke-related death and disability. He is the principal investigator (PI) or Co-PI of multiple international multicentre randomized trials, including ENRICH-AF (NCT03950076; Lancet 2023), OCEANIC-STROKE (NCT05686070), SATURN-MRI (NCT03936361), CoVasc-ICH 2 (NCT06587737 ), and INTERCEPT (NCT05723926). He has also held central leadership roles in the ANNEXa-I (NEJM 2024), PACIFIC-STROKE (Lancet 2022), and NAVIGATE-ESUS (NEJM 2018) trials. Shoamanesh is the founding Chair of the Canadian Hemorrhagic Stroke Trials Initiative (CoHESIVE), and was the lead author of the first Canadian Stroke Best Practice Recommendations on the Management of Spontaneous Intracerebral Hemorrhage.

Shoamanesh has published over 170 peer-reviewed manuscripts in top-tier scientific journals. He serves on the editorial boards of Stroke, the International Journal of Stroke, and the Canadian Journal of Neurological Sciences. He is an active contributor to international scientific meetings and previously co-chaired the World Stroke Congress (World Stroke Organization) and the World Intracranial Hemorrhage Conference.

His research program receives funding from several bodies, including the Canadian Institutes of Health Research, National Institutes of Health, Heart and Stroke Foundation of Canada, Brain Canada, the Australian Government Medical Research Future Fund, and various industry partners. His contributions have been recognized by numerous prestigious national and international accolades from esteemed organizations, such as the American Academy of Neurology (Pessin Award), American Heart/Stroke Association (Globus Award, Siekert Award, Dudley White Award), American Neurological Association (Denny-Brown Award), European Stroke Organization (Young Investigator Award, Scientific Excellence Award), Heart and Stroke Foundation of Canada (National New Investigator Award, Barnett Scholarship) and the World Stroke Organization (Future Leaders Program).

Jessica Vincent

Head of Operations

Jessica Vincent has more than 15 years’ experience in coordinating and managing large, international clinical trials. She holds an Honours Bachelor of Science Degree from Queens University, and a Master of Clinical Epidemiology Degree from the University of Newcastle.

Amanda Taylor

Associate Program Manager

Amanda Taylor is an Associate Program Manager who currently coordinates trials in stroke, and has experience conducting trials in acute coronary syndrome and arrhythmia. Amanda joined PHRI in 2007. She holds a Bachelor of Science Degree (Honours) in Neurobiology from Brock University.